Results 171 to 180 of about 12,098 (189)

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion. [PDF]

Neurooncol Adv
Cerretti G, Padovan M, Guerriero A, Maccari M, Bosio A, Caccese M, Cella E, Pintacuda G, Librizzi G, Lombardi G.   +9 more
europepmc   +1 more source

Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

Clin Lung Cancer
Fan Y, Drilon A, Chiu CH, Loong HHF, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ROS1 Fusions in Cancer: A Review

Future Oncology, 2016
The ROS1 gene belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. A literature review identified a ROS1 fusion in 2.54% of the patients with lung adenocarcinoma and even higher frequencies in spitzoid neoplasms and inflammatory myofibroblastic tumors.
Arnaud, Uguen, Marc, De Braekeleer
openaire   +2 more sources

RET, ROS1 and ALK fusions in lung cancer

Nature Medicine, 2012
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for
Kengo, Takeuchi, Manabu, Soda, Yuki, Togashi, Ritsuro, Suzuki, Seiji, Sakata, Satoko, Hatano, Reimi, Asaka, Wakako, Hamanaka, Hironori, Ninomiya, Hirofumi, Uehara, Young, Lim Choi, Yukitoshi, Satoh, Sakae, Okumura, Ken, Nakagawa, Hiroyuki, Mano, Yuichi, Ishikawa   +15 more
openaire   +2 more sources

Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case

Journal of Pediatric Hematology/Oncology, 2020
Congenital glioblastoma (GBM) is a rare brain tumor of infancy. While histologically they resemble pediatric and adult GBM, growing evidence suggests a distinct molecular profile. We report the case of a 7-day-old infant female with congenital GBM found to harbor a GOPC-ROS1 fusion.
Susan L, Whiteway, Aaron M, Betts, Erika R, O'Neil, Adam L, Green, Ahmed, Gilani, Brent A, Orr, Derek A, Mathis   +6 more
openaire   +2 more sources

Differential crizotinib efficacy among ROS1 fusion partners in ROS1-positive non-small cell lung cancer.

Journal of Clinical Oncology, 2017
9067 Background: ROS1 rearrangement non–small-cell lung cancers can be effectively treated with ALK inhibitor such as crizotinib, but the response magnitude and duration are heterogeneous. Several ROS1 fusion partners have been identified, but few studies have focused on the effects of different fusion partners on the efficacy of crizotinib. Methods:
Shun Lu, Ziming Li
openaire   +1 more source

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling

Lung Cancer, 2016
Crizotinib was approved for the treatment of ROS1-rearranged non-small cell lung cancer (NSCLC) patients in the US on 11 March, 2016. Interestingly no one companion diagnostic test (CDx) has been approved simultaneously with this approval of crizotinib. Hence, an ideal and adequate CDx will have to be able to identify ROS1 fusions without the knowledge
Viola Weijia, Zhu, Daya, Upadhyay, Alexa B, Schrock, Kyle, Gowen, Siraj M, Ali, Sai-Hong Ignatius, Ou   +5 more
openaire   +2 more sources

Orthogonal Testing Unravels a Novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A Practical Approach to Molecular Testing for Actionable Fusion Variants

JCO Precision Oncology, 2023
Hiba G. Narvel, So Yeon Kim, Aspan M. Shokrekhuda, Perry R. Cohen, K. H. Ramesh, Sheila R. Solomon, Paul K. Paik, Balazs Halmos   +7 more
openaire   +2 more sources